Minimum inhibitory concentrations of equine Corynebacterium pseudotuberculosis isolates (1996-2012).

BACKGROUND: Few studies report the minimum inhibitory concentrations for antimicrobials against equine Corynebacterium pseudotuberculosis isolates. HYPOTHESIS/OBJECTIVES: To evaluate trends in the in vitro activities of 20 antimicrobials against equine Corynebacterium pseudotuberculosis isolates from 1996 to 2012 and to determine if a relationship exists between the minimum inhibitory concentration (MIC) and location of the abscess. ANIMALS: Corynebacterium pseudotuberculosis isolates from 196 horses with naturally occurring disease. METHODS: Retrospective and cross-sectional design. Medical records were reviewed to obtain clinical and MIC data. Minimum inhibitory concentrations were determined by the microdilution technique. The MIC results over 3 periods were compared (1996-2001, 2002-2006, 2007-2012). RESULTS: The MIC90 values for clinically relevant antimicrobials were as follows: chloramphenicol ≤ 4 µg/mL, enrofloxacin ≤ 0.25 µg/mL, gentamicin ≤ 1 µg/mL, penicillin =0.25 µg/mL, rifampin ≤ 1 µg/mL, tetracycline ≤ 2 µg/mL, trimethoprim-sulfamethoxazole (TMS) ≤ 0.5 µg/mL, ceftiofur =2 µg/mL, and doxycycline ≤ 2 µg/mL. There were no significant changes in MIC results over the study period. There was no relationship between MIC patterns and abscess location. CONCLUSIONS AND CLINICAL IMPORTANCE: The MIC50 and MIC90 values of antimicrobials evaluated in this study for equine isolates of C. pseudotuberculosis did not vary over time. Abscess location was not associated with different MIC patterns in cultured isolates. Several commonly used antimicrobials are active in vitro against C. pseudotuberculosis in vitro.

Pharmacokinetics and preliminary safety evaluation of azithromycin in adult horses.

Azithromycin is widely used in foals but has not been studied in adult horses. The goals of this study were to determine the pharmacokinetic profile and to make a preliminary assessment of the safety of azithromycin in adult horses. Azithromycin was administered intravenously (5 mg/kg) and intragastrically (10 mg/kg) to six healthy mares in a crossover design. Serial plasma samples, blood neutrophils, and pulmonary macrophages were collected for the measurement of azithromycin concentrations. Azithromycin was also administered orally (10 mg/kg) once a day for 5 days to five healthy mares for preliminary evaluation of safety in adult horses. The bioavailability of azithromycin following intragastric administration was 45 ± 12%. Concentrations within peripheral neutrophils and bronchoalveolar macrophages were several fold higher than that of plasma. Mild decreases in appetite (n = 3) and alterations in fecal consistency (n = 3) were noted following repeated oral administration. The pharmacokinetic profiles of azithromycin in adult horses, especially the slow elimination rate and intraneutrophil and intrapulmonary macrophage accumulation, demonstrate that it is conducive to use in this age group. Because of the gastrointestinal alterations noted, further studies are warranted before azithromycin can be recommended for use in adult horses.

Comparison of five real-time PCR assays for detecting virulence genes in isolates of Escherichia coli from septicaemic neonatal foals.

Fifty-five isolates of Escherichia coli from septicaemic neonatal foals were used to validate five real-time pcr assays targeting different known virulence factor genes: curli fibre (csgD), ferric hydroxamate uptake (fhuA), type 1A pilin (fimA), aerobactin (lutA) and yersiniabactin (fyuA). A pcr assay targeting a universal sequence of the bacterial 16S rrna gene served as quality control. The pcr assays showed good analytical specificity and sensitivity on the basis of sequencing the pcr products, their lack of cross-reactivity with non-E coli organisms, high amplification efficiency and a limit of detection as low as 25 E coli colony-forming units. There were differences between the detection rates and amplification efficiencies for the five virulence genes. The pcr assays targeting genes csgD, fhuA and fyuA were able to detect all 55 E coli isolates, with gene csgD having the best amplification efficiency. The lowest detection rate and amplification efficiency of the E coli isolates was found for the lutA gene.

Bilateral tibial components of different cementless designs and materials. Microradiographic, backscattered imaging, and histologic analysis.

Postmortem evaluation was conducted on two cementless knee prostheses considered clinically successful. The two retrieved uncemented porous-coated tibial components of different designs, and materials were evaluated by microradiography, backscattered electron (BSE) imaging, and light microscopy. The right prosthesis, in place for 25 months, was a Porous-Coated Anatomic (PCA) implant with double-layered, sintered, cobalt-chromium alloy beads. The left prosthesis was a Natural-Knee (N-K) implant with a porous coating of cancellous-structured pure titanium implanted for 19 months. A quantitative microradiographic index, the appositional bone index (ABI), was developed to indicate the probability of bone ingrowth occurring into the porous coating. The ABI is a ratio of bone in apposition with porous coating divided by the total amount of porous coating available. The PCA had an average ABI of 9%, and the N-K, 67%. BSE images of the PCA demonstrated no bone within the porous coating. BSE images of the N-K implant showed bone ingrowth into 22% of the pore volume when porous coating was in apposition to host bone. Histology of the PCA revealed fibrous connective tissue throughout the porous coating and between the porous coating-bone interface. Histology of the N-K implant revealed bone ingrowth and osteoblastic activity along the bone within the porous coating.